What is Leerink Partnrs’ Forecast for RXRX FY2024 Earnings?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Analysts at Leerink Partnrs reduced their FY2024 earnings estimates for Recursion Pharmaceuticals in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($1.48) per share for the year, down from their previous estimate of ($1.45). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q4 2024 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.43) earnings per share.

A number of other analysts have also weighed in on the company. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $8.75.

Recursion Pharmaceuticals Trading Down 2.7 %

NASDAQ RXRX opened at $7.33 on Friday. The company’s 50-day simple moving average is $6.90 and its two-hundred day simple moving average is $6.95. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $15.74. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -4.79 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Insiders Place Their Bets

In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total transaction of $76,923.84. Following the completion of the sale, the director now directly owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. The trade was a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,894 shares of company stock valued at $279,279. 15.75% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the period. Hsbc Holdings PLC lifted its stake in Recursion Pharmaceuticals by 26.0% during the 2nd quarter. Hsbc Holdings PLC now owns 27,972 shares of the company’s stock valued at $206,000 after acquiring an additional 5,764 shares during the period. Public Employees Retirement Association of Colorado purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $129,000. Ensign Peak Advisors Inc increased its stake in shares of Recursion Pharmaceuticals by 2.5% in the second quarter. Ensign Peak Advisors Inc now owns 408,986 shares of the company’s stock worth $3,067,000 after acquiring an additional 10,050 shares during the period. Finally, Xponance Inc. purchased a new position in shares of Recursion Pharmaceuticals during the second quarter worth $98,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.